Blincyto (blinatumomab) / Astellas, Amgen 
Welcome,         Profile    Billing    Logout  
 29 Diseases   78 Trials   78 Trials   3560 News 


«12...56789101112131415...4445»
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Imbruvica (ibrutinib) / AbbVie, J&J
    Trial completion date, Trial primary completion date:  Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Feb 3, 2023   
    P2,  N=20, Recruiting, 
    Therefore, further prospective randomized clinical studies should be conducted to improve the long-term efficacy of immunotherapy. Trial completion date: Jan 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Sep 2023
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Clinical, Review, Journal:  PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (Pubmed Central) -  Jan 31, 2023   
    These modalities have demonstrated improved remission rates with reduced toxicity compared to chemotherapy. The role of immunotherapy in the treatment of newly-diagnosed and relapsed patients will be more precisely defined in the near future.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Review, Journal:  Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia. (Pubmed Central) -  Jan 31, 2023   
    On the other hand, the infection scenario in the CAR-T setting is quite peculiar: In these patients, infections are more frequent in the first month after infusion and are predominantly bacterial. As the time moves away from day zero, viral infections become more frequent, occurring mainly in patients who have had prolonged cytopenia and major cytokine release syndrome.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    A Case of Multiply Relapsed B-ALL (Poster Area) -  Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_130;    
    Survives a septic shock admission and receives Vinc/Dex x 3 before Blinatumomab...She receives Inotuzumab, Prednisone & frequent IT therapy...She then receives 3 cycles Temozolamide and then is diagnosed with methotrexate-related intracerebral toxicity...Hickman line placement pre-CAR T leads to arterial puncture with massive neck hematoma, requiring prophylactic ventilation and ICU stay. She receives her CAR T cell therapy relatively uneventfully, with Gr I CRS and no evidence of ICANS, and is in morphological remission 1 month post CAR T. She obtains her degree in early childhood development in April 2022 and remains in remission till this day.
  • ||||||||||  Real Life CAR-T for ALL Adult Patients (Poster Area) -  Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_116;    
    In our series of 10 infused heavily pretreated adult B-ALL patients, brexu-cel was effective and well tolerated.The incidence of CRS, ICANS, and other toxicities was very low. ORR at day+30 after infusion is very promising, despite a longer follow-up and further study are necessary to confirm these data.
  • ||||||||||  TP53 Mutations: Impact in Childhood Outcomes after CD19-CAR T-cell Therapy (Poster Area) -  Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_95;    
    In our series, all patients were refractory or had CD19 negative relapses, most of them before 6 months after CAR-T. The role of early consolidation with HSCT in patients achieving complete remission after CAR-T should be explored.
  • ||||||||||  Donor-derived CAR-T Cells Co-infusion with T-depleted HSCT (Poster Area) -  Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_55;    
    P1/2
    Allogeneic haploidentical donor-derived CAR-T cells can be safely co-infused with the αβ-T cell-depleted grafts, with minimal CAR-T-related toxicity, without compromise of engraftment and GVHD control. CAR-T cells expand and persist as expected.
  • ||||||||||  Tecartus (brexucabtagene autoleucel) / Gilead
    Cost-effectiveness of Brexucabtagene for Refractory/Relapsed Acute Lymphoblastic Leukemia (Poster Area) -  Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_35;    
    Expected overall survival (OS) is particularly poor (i.e. less than 12 months) in patients relapsing or not responding after/to frontline therapy (R/R) despite being offered standard of care (SOC) with targeted agents (Blinatumomab (BLIN), Inotuzumab Ozogamicin (INO)) or chemotherapy (CIT), +/- tyrosin-kinase inhibitors (TKI), possibly followed by allogeneic stem cell-transplantation (aSCT). Brexucabtagene autoleucel is a cost-effective alternative to SOC for adult patients with R/R LLA, both Ph+ and Ph-.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Review, Journal:  Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions. (Pubmed Central) -  Jan 24, 2023   
    This review provides insight into use of cellular therapy in MRD positivity and decreasing donor chimerism. It also discusses various modalities of combining cellular therapy with novel agents and discussing the impact of chimeric antigen receptor T-cell therapy in the setting of post allo-HCT relapse both as consolidative therapy and as a bridge to second transplant.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Super-refractory status epilepticus during blinatumomab initiation for B-cell acute lymphoblastic leukemia. (Pubmed Central) -  Jan 10, 2023   
    Our patient had a complete return to baseline despite enduring encephalopathy, refractory subclinical seizures requiring prolonged therapeutic burst suppression and MRI signal changes. This case demonstrates that super-refractory status epilepticus is a possible neurotoxic adverse effect of blinatumomab treatment, which responds well to conventional protocols for acute refractory seizures.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Blinatumomab in Relapsed/Refractory Burkitt Lymphoma. (Pubmed Central) -  Jan 9, 2023   
    Blinatumomab treatment was a successful bridging treatment to stem cell transplantation in 3/9 patients. The response to blinatumomab varied widely, and only one patient survived longer term, but activity in patients with r/r BL was evident in some patients, with its use being safe, warranting its prospective investigation.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Review, Journal:  Management of acute lymphoblastic leukemia in older adults. (Pubmed Central) -  Jan 7, 2023   
    With the advent of targeted agents, such as monoclonal antibodies and bispecific T-cell engagers, a number of options have proven themselves to be effective in the elderly and optimal for tolerability. Here, we review and discuss the literature addressing regimens that use new agents, such as blinatumomab, inotuzumab ozogamicin, and venetoclax, and those that use modified dosing strategies of traditional chemotherapy.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Blinatumomab-Associated Elevation of Liver Enzymes. (Pubmed Central) -  Jan 7, 2023   
    Here, we review and discuss the literature addressing regimens that use new agents, such as blinatumomab, inotuzumab ozogamicin, and venetoclax, and those that use modified dosing strategies of traditional chemotherapy. No abstract available
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial completion date, Trial primary completion date:  Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Jan 4, 2023   
    P1,  N=44, Active, not recruiting, 
    This large, real-world data set of adults with B-cell ALL treated with blinatumomab confirms efficacy outcomes from published studies. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, blinatumomab subcutaneous / Amgen
    Trial completion date, Trial primary completion date:  A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients (clinicaltrials.gov) -  Dec 23, 2022   
    P1/2,  N=105, Recruiting, 
    Due to susceptibility and early onset of PCP in ALL patients received TKI combined with blinatumomab therapy, so we should be alert to PCP when pulmonary infection occurred. Trial completion date: May 2025 --> Jul 2026 | Trial primary completion date: Jan 2024 --> Jan 2025